Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_assertion type Assertion NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_head.
- NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_assertion description "[Thirteen primary NSCLC heterotransplant models were used to test four treatment regimens, including platinum-based chemotherapy with and without bevacizumab (VEGF-neutralizing antibody) or HDGF-H3 (HDGF-neutralizing antibody) and chemotherapy with bevacizumab and HDGF-H3.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_provenance.
- NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_assertion evidence source_evidence_literature NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_provenance.
- NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_assertion SIO_000772 23695169 NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_provenance.
- NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_assertion wasDerivedFrom befree-20150227 NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_provenance.
- NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_assertion wasGeneratedBy ECO_0000203 NP769995.RAceNBb6az5u5BMYLxk1DhTBYig_3Q816h-GzsNl3EKZ8130_provenance.